Fermenta Biotech Ltd. stands out in the Pharmaceuticals & Drugs sector with strong profitability metrics, despite facing revenue challenges. While its peers exhibit varied performance, Fermenta’s low PE ratio and respectable ROE position it well for value seekers. Sun Pharma and Divi’s Laboratories are growth leaders, but their high valuations may deter value-focused investors.

• • Fermenta Biotech has a low PE ratio of 14.04, making it attractive for value investors.
• • Sun Pharma leads in revenue growth YoY at 8.42% and a robust EPS of 45.55, but is significantly overvalued with a PE of 87.59.
• • Divi's Laboratories shows high profitability margins but has experienced declining revenue growth, raising concerns about sustainability.
• • Cipla Ltd. and Dr. Reddy's Laboratories demonstrate strong profitability and relatively low valuations, making them good alternatives.
• • The sector shows differentiated performance, with several companies operating at high valuations despite variable growth prospects.